2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate:Exports & Compliance White Paper 2026

I. Executive Summary

2-Ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate (CAS 1911578-98-7, nominal molecular weight 495.4 grams per mole) is a single-diastereomer aryl phosphoramidate used to install masked phosphate groups in ProTide prodrug chemistry. It is a specified advanced intermediate supplied for further manufacture only: it has no approved therapeutic indication of its own, it is not a finished drug product, and references to nucleotide phosphoramidate prodrugs in this paper describe the downstream customer's chemistry rather than any treatment claim. The commercial interest in this reagent is nonetheless outsized relative to its volume, because the pandemic-era expansion of antiviral nucleotide programmes permanently changed the scale, geography and documentation standards of the phosphoramidate intermediate market.

Three attributes govern every purchase decision. The first is chirality at phosphorus: with four different substituents around the pentavalent centre, the Sp and Rp diastereomers are distinct compounds with distinct reactivity, and the whole value of the reagent rests on delivering one of them at very high purity. The second is hydrolytic fragility: the pentafluorophenoxy group is an excellent leaving group by design, which makes the reagent reactive in the intended coupling and unstable against moisture everywhere else. The third is documentation, since programmes using this chemistry operate under ICH Q7, Q11, Q3D and M7 expectations long before the asset is approved anywhere.

For procurement teams the practical implication is that lead time and working capital, not unit price, dominate costing. Campaign slots in multipurpose plants must be reserved early, cold-chain logistics add real cost per kilogramme, method transfer for chiral purity takes months, and freedom-to-operate screening has to be solved before a supply agreement is signed. This paper maps each of those steps and the regional ecosystems able to serve them.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule combines three structural elements in one reagent: the L-alanine 2-ethylbutyl ester fragment that will later be cleaved metabolically, a phenyl ester that moderates reactivity and lipophilicity, and a pentafluorophenyl group that serves as the leaving group in the phosphorus-nucleoside coupling step. It is normally handled as an off-white solid or viscous oil, freely soluble in aprotic solvents such as acetonitrile, esters, ethers and chlorinated solvents, and essentially insoluble in water, where it hydrolyses. Supplier specifications typically fix appearance, identity by proton, carbon and phosphorus nuclear magnetic resonance, assay, diastereomeric purity, water content and residual starting phenols.

• Phosphorus stereochemistry is the product:Because the tetrahedral arrangement around phosphorus binds four different substituents, the centre is configurationally stable and the two diastereomers behave as separate materials. They differ in coupling rate and selectivity and generate different impurity profiles, so the minor isomer is a specified impurity rather than an analytical curiosity. Phosphorus-31 spectroscopy gives a direct handle on identity and isomer ratio.
• Leaving-group reactivity versus hydrolytic lifetime:The five ring fluorines withdraw electron density and make pentafluorophenol an unusually good leaving group, which is why coupling proceeds under mild conditions. The same electronics make the phosphorus centre water-sensitive: ingress gives free pentafluorophenol, phenyl phosphate species and acidic hydrolysis products. Water activity and temperature therefore define shelf life.

2.2 Synthesis and Manufacturing Technologies

At route-class level, manufacture is a controlled substitution sequence on a phosphoryl electrophile, with the amino acid ester as the nucleophilic partner; the order in which the two aryl groups are retained or displaced determines which one becomes the leaving group. Beyond that this paper stays abstract. What matters commercially is that each displacement is exothermic, that low temperature limits bis-substitution and isomer formation, and that the crude carries a predictable family of related substances that purification must separate.

• Diastereomer control through crystallisation or chiral chromatography: Suppliers reach specification either by crystallisation-driven enrichment, which exploits the different physical properties of the two diastereomers, or by preparative chromatography such as supercritical fluid chromatography or simulated moving bed at larger scale. The chromatographic route consumes large solvent volumes and requires dedicated recovery infrastructure, and that infrastructure cost is usually visible in the price.
• GMP-aligned versus research-use-only campaigns: Programmes preparing regulatory filings ask for ICH Q7-aligned starting-material qualification, Q11-style process understanding, Q3D elemental screening and M7 assessment of any alerting residues. Early-stage programmes buy research-use-only material released against a simpler specification. The same plant can serve both, but only if the quality system explicitly separates campaign documentation, equipment cleaning and change control.

2.3 Core Application Matrix

• Advanced intermediate for ProTide phosphoramidate programmes: The dominant use is transfer of the whole masked phosphate unit onto a nucleoside or other alcohol-bearing candidate, after which the aryl and amino acid ester groups are removed metabolically in the patient. It is a building block, not a drug, and carries no therapeutic indication of its own.
• Analytical reference and starting-material qualification material: Laboratories buy characterised lots, and frequently the isolated minor diastereomer, to develop and validate chiral methods, to identify impurities arising from the coupling step and to build purge-factor arguments for potentially genotoxic residues.
• Platform use beyond nucleosides: The same phosphoramidate masking logic is applied to phosphate and phosphonate-bearing candidates outside antiviral chemistry, including oncology and metabolic programmes, usually at research-use-only grade and under confidentiality.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand between 2020 and 2022 was a shock rarely seen in fine chemicals: campaigns were commissioned before analytical packages were mature, plants were converted in months, and prices reflected urgency rather than cost. That surge has normalised, leaving multipurpose phosphoramidate capacity looking for programmes. Current demand is lumpy and programme-linked: a candidate entering late-stage development absorbs tens of kilogrammes within two quarters, while a discontinued asset removes the volume entirely.

3.2 Capacity Distribution and Export Flows

China and India hold most installed campaign capability, in multipurpose plants in Hubei, Jiangsu and Zhejiang and in Hyderabad, Gujarat and Bengaluru contract organisations combining process research with chiral analytics and cold-chain export routines. Western Europe and North America retain a smaller, higher-touch tier serving confidential programmes and research-use-only distribution. Export classification varies between the heading for compounds with other nitrogen function and that for organophosphorus compounds, so secure a binding ruling early.

3.3 Market Bifurcation and Pricing Dynamics

Three tiers exist. Catalogue research-use-only lots sell at high price per gram in small quantities, justified by analytical release and cold-chain shipping rather than chemistry. Kilogramme campaigns under quality agreements cost multiples of that because campaign design, cleaning validation, chiral method operation and documentation dominate. Custom route development is priced as a service. Since the post-pandemic correction, low offers circulate widely, and the decisive question is whether they still include validated chiral data and impurity identification.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Because annual volumes are small and the uses are confidential, this intermediate rarely carries the inventory status of a commodity molecule. That shifts compliance work onto the importer: verifying status per destination, documenting the exemption being relied upon, and preparing the quality documentation that downstream filings will demand.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH status and the low-volume and PPORD routes: Most European recipients import well below one tonne per year, so shipments often rely on either the tonnage threshold or the exemption for product and process oriented research and development, which carries defined conditions and an expiry date. Either route requires written evidence and an internal owner, because both are defended at audit rather than at customs.
• PFAS adjacency and perfluoroaromatic declarations: Buyer questionnaires increasingly ask whether a material contains fluorinated chemistry. The pentafluorophenyl ring is a perfluoroaromatic, but the widely used restriction definition from the multi-country proposal turns on fully fluorinated methyl or methylene carbon atoms, which this ring does not contain. Suppliers should answer with that distinction stated explicitly, supported by a declaration of intentionally added per- and polyfluoroalkyl substances elsewhere in the campaign.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory status and the research exemption: If the CAS is not listed as active on the inventory portion relied upon, commercial import requires either a Premanufacture Notice or strict reliance on the research and development exemption conditions, including labelled quantities, restricted personnel and disposal at the end of the exemption period. Both paths are document-heavy and should be settled before shipping.
• Starting-material justification in downstream filings: Customers filing investigational or commercial applications must justify where synthesis begins and qualify this reagent accordingly, which drives requests for route description, impurity fate, purge evidence and change control history. It also fixes the boundary of what suppliers can disclose, since competing programmes frequently share the same reagent supply.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Fluorine content makes environmental performance unusually concrete for this molecule. Three questions arrive with nearly every request for quotation: how fluorinated waste is destroyed, whether the material triggers perfluoroalkyl declarations, and how much solvent the purification route consumes.

5.1 Carbon Footprint and Circular Economy

Cradle-to-gate emissions are dominated by purification rather than by bond formation. Preparative chromatography at campaign scale can consume tonnes of solvent per kilogramme of product, so the single largest lever is switching from normal-phase purification to supercritical fluid chromatography with carbon dioxide recovery, followed by multi-effect solvent recovery and reduced low-temperature holding time. Cold-chain air freight adds a further layer, since refrigerated air transport carries a far higher emissions intensity per kilogramme than sea freight with qualified temperature control, and buyers increasingly ask for that distinction explicitly in transport emissions reporting.

5.2 Sustainable Sourcing and Traceability

The distinctive issue is fluoride accountability. Fluorinated aromatic streams are not amenable to biological treatment and must be destroyed by high-temperature incineration with hydrogen fluoride capture and lime neutralisation producing calcium fluoride for disposal, with wastewater consents monitored through adsorbable or total organic fluoride rather than through conventional oxygen demand. Alongside that, buyers expect documented chain of custody for the amino acid derived fragment, including non-animal origin and transmissible spongiform encephalopathy status declarations, occupational hygiene controls for phenol handling, and confirmed absence of intentionally added perfluoroalkyl substances elsewhere in the campaign.

VI. Supply Chain Resilience and Export Logistics

Cold chain is a hard requirement rather than a preference, because hydrolytic degradation during transit irreversibly consumes specification margin that cannot be recovered by rework. Every element of the shipping system is therefore designed around water activity and temperature rather than around containment alone.

6.1 Packaging Standards and Moisture/Contamination Control

• Inert, low-permeability primary packaging: Typical construction is amber glass or lined high-density polyethylene closures with nitrogen or argon headspace and desiccant, sealed inside foil-laminate moisture-barrier pouches and then insulated shippers. Because degradation follows water activity rather than liquid contact, liner permeation and closure torque are the specifications that matter most.
• Qualified lanes and temperature monitoring: Shippers should be validated against recognised thermal profiles for the lane and season, with calibrated data loggers in every consignment and a documented excursion protocol supported by real stability data. Avoid direct refrigerant contact with glass primaries, and agree in advance who owns material whose logger shows a breach.

6.2 Dangerous Goods Identification and Transit Protocols

Classification must be issued per lot from the supplier's own data. Where the notified hazard profile is limited, consignments travel as non-regulated chemicals; where acute toxicity or corrosivity claims apply, packaging groups and labelling change and air options narrow. Where dry ice is used, IATA packing instruction 954 and the UN 1845 declaration apply, with sublimation limits set by each airline. Buyers with predictable schedules therefore prefer sea freight in controlled containers under logger surveillance, reserving air for genuine shortages.

VII. Enterprise Global Expansion Strategy Guide

Three moves protect programmes that depend on this reagent.

1. Transfer the analytical method before transferring the material: Move the chiral chromatographic method and the phosphorus-31 nuclear magnetic resonance procedure into your own laboratory, run a crossover study on at least three lots, fix integration rules in writing and secure reference quantities of both diastereomers. Divergent results between two laboratories are the most common cause of rejected lots and delayed campaigns.
2. Contract the cold chain and the stability commitment: Specify lane-validated packaging, logger requirements, pre-agreed excursion disposition and scheduled stability updates, since these are slow-moving inventories. Tie retest dating to real data rather than to convention, and require the supplier to notify changes in primary packaging immediately.
3. Resolve freedom to operate before reserving capacity: Screen patent coverage of both the reagent and the intended products in each target market, confirm licensing position and territorial restrictions, and align campaign timing with expiry or licence scope. Use confidentiality agreements and dedicated equipment rather than opportunistic spot purchases where programme visibility is material.

VIII. Conclusion

This reagent is the archetype of a modern advanced intermediate: small volume, high unit value, disproportionate influence on downstream impurity profile, and a qualification burden that falls as heavily on analytical method agreement as on chemical specification. Suppliers who invest in chiral analytics, stability science and campaign documentation will keep capturing the programmes that matter, while those competing on price alone will keep losing them at technical due diligence.

For 2026, the outlook is one of normalised capacity serving a broader set of phosphate prodrug programmes than existed before the pandemic. Buyers should plan six to twelve months of qualification lead time, hold buffer inventory against cold-chain failures, and treat freedom-to-operate analysis as a procurement input. The Guidechem ecosystem mapped below identifies counterparties able to operate at that level.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate supply chain:

• China: multipurpose phosphoramidate campaign capacity: Plants in Hubei, Jiangsu and Zhejiang converted capacity rapidly during the pandemic and now offer kilogramme campaigns with increasingly mature impurity packages, cold-chain export routines and both research-use-only and quality-agreement release paths.
• India: Hyderabad, Bengaluru and Gujarat contract organisations: Strongest combination of process research, chiral method development and English-language technical documentation, frequently supplying route scouting, diastereomer separation development and scale-up alongside material, and comfortable hosting customer audits.
• Western Europe and North America: confidential high-touch supply: Smaller specialists and distributors provide analytical reference lots, tightly controlled cold-chain distribution and campaigns for programmes where confidentiality, proximity and short lead times outweigh unit cost.